Inflammatory Bowel Disease
Tools: Clinical tools may be available through the Services. These tools may require you to provide information for the tools to operate. These tools may store information that you provide on our servers. Additional Forms and Emails: We may also ask you to provide additional information after you register if you want to obtain additional services or information or to resolve complaints or concerns. Market Research: From time to time, you may be invited to participate in a sponsored or unsponsored market research survey through an email invitation, on-site pop-up or some other means. The survey may be administered by one of our companies or a third party market research company. When participating in such a survey, in addition to providing your responses to the survey questions you may be asked to provide personally identifiable information that may be combined with information that you have already provided at registration or that we have received from third party sources, as described in this Privacy Policy. The section of this Privacy Policy entitled "Uses and Disclosures We Make of Information," below, describes how we use and disclose information about your participation in market research surveys offered through the Services. Use of Cookies and Web Beacons We collect non-personally identifiable information about your use of the Services through the use of cookies. A cookie is a small data file that your browser allows us to place on your hard drive so we can associate you with the device you are using. We may assign cookies to devices that accesses the Services to: (i) track usage across the Professional Sites and Services; (ii) help us dynamically generate advertising and content to users of the Services; and (iii) assess which Professional Site pages and Services you access. more things http://emedicine.medscape.com/article/179037-overview
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Despite these numbers, there is still a significant portion of IBD patients who are underserved by current pharmacological treatments. About BioLineRx BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013. For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store. Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-7040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013. what google did to me http://www.marketwatch.com/story/biolinerx-announces-new-positive-results-in-phase-2a-trial-for-orally-available-inflammatory-bowel-disease-treatment-2013-11-26
Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Inflammatory bowel disease (IBD) is an immune-mediated disease in which the bodys own immune system attacks the parts of the digestive system of the human body. Such disease involves inflammation of lower gastrointestinal tract and causes irreversible damage to the bowel. Ulcerative colitis and Crohns disease are the two major forms of IBD; both having distinct pathologic and clinical characteristics. IBD is a difficult to manage medical condition with a higher morbidity rate and thus its diagnosis and management is of utmost importance. The global inflammatory bowel disease market is categorized as follows: Product type Biologic therapies (biological drugs) Currently, the developed global markets of North America and Europe make up for the majority of the inflammatory bowel disease market in the world. Emerging markets of Asia mainly India, Russia and Japan as well as countries of Middle East and Latin America are also expected to show strong growth due to rising incidences of such diseases owing to increased industrialization, modernization of the population and drastic lifestyle changes. One of the key factors driving the growth of this market is the increase in use of biological therapies such as monoclonal antibodies. However, difficulties involved in affording the expensive treatments of such diseases may pose challenge to growth of inflammatory bowel diseases market majorly in developing nations. Some of the key players in this industry are Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Alcon, Inc., Baxter International, Inc., Johnson & Johnson, Sequella, Inc., Sanofi-Aventis LLC, Osiris Therapeutics, Inc., AstraZeneca PLC, Eisai Co. Ltd., Cephalon, Inc., Celltrion, Inc., Pfizer, Inc., Pluristem Therapeutics, Inc., Soligenix, Inc. and Ore Pharmaceuticals, Inc. This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include North America This report provides comprehensive analysis of Market growth drivers visit your url http://www.international.to/index.php?option=com_content&id=51360:inflammatory-bowel-disease-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019&Itemid=446
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Despite these numbers, there is still a significant portion of IBD patients who are underserved by current pharmacological treatments. About BioLineRx BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013. For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store. Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-7040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2013. what google did to me http://www.marketwatch.com/story/biolinerx-announces-new-positive-results-in-phase-2a-trial-for-orally-available-inflammatory-bowel-disease-treatment-2013-11-26
Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Inflammatory bowel disease (IBD) is an immune-mediated disease in which the bodys own immune system attacks the parts of the digestive system of the human body. Such disease involves inflammation of lower gastrointestinal tract and causes irreversible damage to the bowel. Ulcerative colitis and Crohns disease are the two major forms of IBD; both having distinct pathologic and clinical characteristics. IBD is a difficult to manage medical condition with a higher morbidity rate and thus its diagnosis and management is of utmost importance. The global inflammatory bowel disease market is categorized as follows: Product type Biologic therapies (biological drugs) Currently, the developed global markets of North America and Europe make up for the majority of the inflammatory bowel disease market in the world. Emerging markets of Asia mainly India, Russia and Japan as well as countries of Middle East and Latin America are also expected to show strong growth due to rising incidences of such diseases owing to increased industrialization, modernization of the population and drastic lifestyle changes. One of the key factors driving the growth of this market is the increase in use of biological therapies such as monoclonal antibodies. However, difficulties involved in affording the expensive treatments of such diseases may pose challenge to growth of inflammatory bowel diseases market majorly in developing nations. Some of the key players in this industry are Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company, Alcon, Inc., Baxter International, Inc., Johnson & Johnson, Sequella, Inc., Sanofi-Aventis LLC, Osiris Therapeutics, Inc., AstraZeneca PLC, Eisai Co. Ltd., Cephalon, Inc., Celltrion, Inc., Pfizer, Inc., Pluristem Therapeutics, Inc., Soligenix, Inc. and Ore Pharmaceuticals, Inc. This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include North America This report provides comprehensive analysis of Market growth drivers visit your url http://www.international.to/index.php?option=com_content&id=51360:inflammatory-bowel-disease-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019&Itemid=446
Replies